Aduro Biotech Announces Breakthrough in Prostate Cancer Treatment

Aduro Biotech Announces Breakthrough in Prostate Cancer Treatment

shutterstock_133427744Aduro Biotech, Inc. a clinical-stage immuno-oncology company, recently announced its first breakthrough since its partnership with Janssen Biotech, Inc.. The company is going to begin toxicology investigations to sustain an Investigational New Drug Application for ADU-741, an immuno-oncology compound that will be tested as a potential prostate cancer treatment.

ADU-741 is a multi-target LADD product candidate created specifically for prostate cancer treatment, as it stimulates the expression of several antigens associated with this cancer. Janssen Biotech, Inc. was accredited last May 2014 as a private global developer and has total commercial rights over ADU-741.

Janssen Biotech has decided to initiate clinical trials for ADU-741 in prostrate cancer treatment due to the promising results from preclinical trials conducted during the initial 8 months of partnership with Aduro Biotech.

Aduro’s LADD is a platform of live, reduced, double-deleted Listeria monocytogenes strains that were developed to instigate a potent innate immune response and to enable a directed, long-lasting adaptive immune response.

Aduro Biotech, Inc. is a company focusing on the development of its LADD Listeria monocytogenes and cyclic dinucleotide (CDN) technology platforms in order to induce potent innate immune responses and drive targeted, long-lasting adaptive immune responses against different types of cancers.

The U.S Food and Drug Administration (FDA) awarded Aduro Breakthrough Therapy status for its innovative immuno-oncology regimens, called CRS-207 and GVAX Pancreas, especially developed for pancreatic cancer. The regimen is currently under evaluation in an on-going Phase 2b clinical study (ECLIPSE). Furthermore, the company has other continuing clinical studies using their LADD platform targeting mesothelioma and glioblastoma. In addition, Aduro is currently developing experimental candidates using synthetic small molecule CDNs, which are proposed to trigger the intracellular STING receptor.

“This is an important validation of our ability to rapidly engineer new product candidates from our LADD platform,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro in a recent press release. “We are pleased to earn the associated milestone payment and importantly to see our technology progress toward clinical trials to evaluate its utility in prostate cancer.”